Attendee search 

ImmuneXcite is a privately held biotech company developing the next generation of immune-activating therapies for cancer and infectious diseases utilizing a novel immunotherapy platform technology. ImmuneXcite’s platform technology, mAbXcite, creates novel monoclonal antibody constructs that trigger a potent immune cell response selectively against disease targets. The mAbXcite technology is based on a unique polysaccharide that signals infection to the immune system. By linking this polysaccharide to monoclonal antibodies (or other targeting moieties like bi-specific mAbs, aptamers, peptides), a recruitment and activation of neutrophils/immune cells against the bound target is triggered, leading to its destruction. The mAbXcite constructs have demonstrated superior efficacy in resistant tumor xenograft models when compared to monoclonal antibodies. The company is currently developing lead therapeutic mAbXcite constructs for high unmet medical needs and breakthrough indications. IND-enabling studies have started and the company has developed an imaging assay that validates the mechanism of action and which can potentially be used as a pharmacodynamic marker for anti-tumor activity in Phase I clinical studies.

ImmuneXcite has a strong patent portfolio and has raised $8 million from angel/private investors and non-dilutive sources (Massachusetts Life Science Center and a SBIR grant from NCI). The company is seeking to raise $14-16 million in its next  financing in the 4th quarter 2014 to support development of its lead compound through completion of Phase I clinical trials. ImmuneXcite’s business development strategy is to establish partnerships/collaborations to maximize the therapeutic potential of its platform technology, and to build its internal pipeline through in-licensing. Active partnering discussions are ongoing.